GKB Ophthalmics to Review Q2 Results After ₹1.8 Crore Q1 Profit

GKB Ophthalmics Ltd will consider its unaudited September 2026 quarter and half-year results on November 12, 2026, following consolidated sales of ₹33.04 crore and net profit of ₹1.8 crore in the June 2026 quarter. The meeting will provide the next formal update on the company's FY27 operating and financial performance.

When will GKB Ophthalmics announce its September 2026 results?

GKB Ophthalmics Ltd has scheduled a board meeting for November 12, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company disclosed the meeting schedule to BSE on October 29.

The September-quarter announcement is the second quarterly earnings update of FY27. It follows the board's August 12 meeting, where directors considered and took on record the unaudited standalone and consolidated results for the quarter ended June 30, 2026.

The board meeting is scheduled as part of the company's regular financial-reporting cycle. Its preceding meetings were held on May 27, 2026 for audited March-quarter and full-year FY26 results, and on August 12 for the June-quarter results.

For designated persons, the trading window had been closed from July 1, 2026, ahead of the results process. It is to reopen 48 hours after the financial results are submitted to the stock exchanges, according to the company disclosure.

What did GKB Ophthalmics report in the June 2026 quarter?

GKB Ophthalmics reported consolidated revenue from operations of ₹33.04 crore in the June 2026 quarter, compared with ₹32.31 crore in the June 2025 quarter, while net profit was ₹1.8 crore. The reported revenue growth was 2.2% year on year.

The June-quarter figures marked a return to profitability, according to the results update. Consolidated operating profit was ₹2.63 crore, compared with ₹0.80 crore in the corresponding quarter of the previous year. Expenses were ₹30.41 crore, against ₹31.51 crore a year earlier.

The company's consolidated sales had varied through FY26. Sales were ₹30.17 crore in September 2025, increased to ₹56.79 crore in December 2025, and stood at ₹29.79 crore in March 2026. The March 2026 sales figure was 3.97% lower year on year.

Why does the November board meeting matter for investors?

The November 12 meeting matters because it will disclose whether the June-quarter profitability and modest sales growth continued into the September quarter. Investors will receive both the standalone numbers and the consolidated financial position for the first half of FY27.

The company has reported materially different sales levels across recent quarters, including ₹56.79 crore in December 2025 and ₹29.79 crore in March 2026. The September result will add another data point on revenue movement after June-quarter sales of ₹33.04 crore.

Operating costs are also relevant in assessing the June-quarter performance. Consolidated expenses declined by ₹1.10 crore year on year in the June 2026 quarter, while operating profit increased to ₹2.63 crore. The forthcoming results will show the reported cost and profit figures for the September quarter, but no forward financial guidance was provided in the available disclosure.

The annual general meeting held on August 25, 2026 approved the FY26 financial statements, director reappointments and limits for specified related-party transactions. Shareholders also approved the decision not to pay a dividend for FY26.

What is the recent financial reporting background for GKB Ophthalmics?

GKB Ophthalmics completed its FY26 results process when its board approved audited standalone and consolidated financial statements on May 27, 2026. The company also stated that it re-appointed internal auditors and did not declare a dividend for the financial year.

The company had earlier reported consolidated net sales of ₹29.79 crore for the March 2026 quarter, down 3.97% year on year. Its standalone March-quarter sales were ₹6.40 crore, down 24.03% from a year earlier. These figures underline the distinction between the standalone business and the consolidated group results.

A subsidiary, GSV Ophthalmics, also approved voluntary liquidation, according to the company-related disclosures. The available information does not state the financial impact of that process on the upcoming September-quarter results.

GKB Ophthalmics has stated that its financial results and related disclosures are uploaded to its website and the BSE website. The November outcome will therefore be the next exchange-filed update on the company's reported performance.

How could the results affect shareholders and company operations?

For shareholders, the September-quarter filing will provide updated reported data on sales, expenses, operating profit and net profit after the June-quarter return to profitability. It will also provide half-year figures, allowing comparison of the first two quarters of FY27 with prior periods.

The announcement does not contain a proposed dividend, expansion programme, or earnings forecast. As a result, the immediate confirmed development is the scheduled approval and release of unaudited results, rather than any announced change in capital allocation or operations.

The company has also obtained shareholder approval for transaction limits involving GKB Vision Private Limited and Lensco - The Lens Company for FY27. These approvals form part of the governance framework disclosed after the annual general meeting, while the November meeting is focused on quarterly and half-year financial statements.

Conclusion

GKB Ophthalmics is due to report its September 2026 quarter and first-half FY27 financial results on November 12. The update follows June-quarter consolidated sales of ₹33.04 crore, 2.2% higher year on year, and a reported net profit of ₹1.8 crore, alongside a rise in operating profit to ₹2.63 crore.

The key item to watch is the board's release of unaudited standalone and consolidated September-quarter and half-year figures. The disclosure will clarify the sales, cost and profitability position following the June-quarter results, and the trading window is set to reopen 48 hours after the exchange submission.